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Lead is an established carcinogen in experi-
mental animals (1,2). Administration of inor-
ganic lead to rats and mice by different routes
resulted in development of renal tumors,
gliomas, and/or lung adenomas. In contrast,
lead is classified as a possible carcinogen in
humans. Results of epidemiologic studies
investigating the association of lead exposures
with cancer are inconsistent and vary according
to the type of cancers reported. For example,
although Wong and Harris (3) reported a non-
signiﬁcant mortality deﬁcit for kidney cancer
[standardized mortality ratio (SMR) = 63.6;
95% conﬁdence interval (CI), 33.9–108.7],
Steenland et al. (4) reported an excess risk
(SMR = 240; 95% CI, 103–471), especially in
the high-lead exposure group. Steenland and
Boffetta (5) summarized the results of the pre-
ceding two epidemiologic studies and six oth-
ers in cohorts of lead smelter and battery
workers exposed decades ago. They concluded
that there was only weak evidence associating
lead with cancer; lung cancer, stomach cancer,
and gliomas were the most likely candidates. 
Many of the epidemiologic studies that
relate lead with cancer are in occupational
settings. To our knowledge, no study has
examined the association between lead and
cancer in the general population. In this
paper, we present the results of our investiga-
tion of the association between blood lead
levels and cancer mortality among whites in
the general population of the United States
using data from the National Health and
Nutrition Examination Survey II Mortality
Study, 1992 (NH2MS). Our analysis is
restricted to whites because both blood lead
concentrations (6) and cancer deaths (7,8)
vary by race, and the number of deaths in
blacks and other races in NH2MS were too
small to provide reliable estimates.
Materials and Methods
The National Health and Nutrition
Examination Survey II (NHANES II) was
conducted between 1976 and 1980 to collect
data from a national probability sample of
the U.S. civilian, noninstitutionalized popu-
lation, 6 months to 74 years of age, a total of
27,801 persons (9). The survey included
standardized questionnaires, physical exami-
nations, and laboratory tests. Blood samples
for lead measurements were drawn from all
children < 7 years of age and from a random
subsample of one-half of the persons ≥ 7
years of age. The NH2MS is a passively fol-
lowed mortality study of the NHANES II
participants (10) designed to examine the
association between factors measured at base-
line and overall or cause-speciﬁc mortality. 
The NH2MS included 9,252 participants
(87.5% whites, 8,091/9,252) who were ≥ 30
years of age at the time of their NHANES II
examination and whose vital status was ascer-
tained after 12–16 years by searching the
National Death Index (National Center for
Health Statistics, Hyattsville, MD) and the
Social Security Administration Death Master
File (11). As of 31 December 1992, 23.3% of
the white participants (1,887/8,091) were
deceased. Blood lead had been measured in a
random subsample consisting of 46.3%
(3,748/8,091) of whites, which forms the
study sample for our analyses; 22.3%
(836/3,748) of this subsample died, with the
underlying cause of death specified for 817
deaths and unspeciﬁed for 19 deaths accord-
ing to International Classiﬁcation of Diseases,
Revision 9 (ICD-9) code (12). Deaths with
unknown underlying cause were excluded
from analyses. We also excluded from analy-
ses a single participant who was lost to follow-
up and 136 participants (equal numbers of
men and women) with missing data for one
or more of the covariates used during analy-
ses. The total number of participants used in
the ﬁnal analyses was 3,592 (1,702 men and
1,890 women). The analytic cohort was
restricted to whites.
The exposure variable of interest, lead
concentration (micrograms per deciliter) in
blood samples measured at the NHANES II
baseline, was determined by a modified
microcup atomic-absorption method (6).
Blood lead was used in the analyses as a con-
tinuous variable where it was (natural) log
transformed, or it was categorized into either
four groups, divided into sample-weighted
quartiles for all study subjects (sample weights
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Lead is classiﬁed as a possible carcinogen in humans. We studied the relationship of blood lead
level and all cancer mortality in the general population of the United States using data from the
National Health and Nutrition Examination Survey II (NHANES II) Mortality Study, 1992,
consisting of a total of 203 cancer deaths (117 men and 86 women) among 3,592 whites (1,702
men and 1,890 women) with average of 13.3 years of follow-up. We used Cox proportional haz-
ard regression models to estimate the dose–response relationship between blood lead and all can-
cer mortality. Log-transformed blood lead was either categorized into quartiles or treated as a
continuous variable in a cubic regression spline. Relative risks (RRs) were estimated for site-spe-
cific cancers by categorizing lead above and below the median. Among men and women com-
bined, dose–response relationship between quartile of blood lead and all cancer mortality was not
signiﬁcant (ptrend = 0.16), with RRs of 1.24 [95% percent conﬁdence interval (CI), 0.66–2.33],
1.33 (95% CI, 0.57–3.09), and 1.50 (95% CI, 0.75–3.01) for the second, third, and fourth quar-
tiles, respectively, compared with the ﬁrst quartile. Spline analyses found no dose response (p =
0.29), and none of the site-specific cancer RRs were significant. Among men, no significant
dose–response relationships were found for quartile or spline analyses (ptrend = 0.57 and p = 0.38,
respectively). Among women, no dose–response relationship was found for quartile analysis (ptrend
= 0.22). However, the spline dose–response results were signiﬁcant (p = 0.001), showing a thresh-
old effect at the 94th percentile of blood lead or a lead concentration of 24 µg/dL, with an RR of
2.4 (95% CI, 1.1–5.2) compared with the risk at 12.5 percentile. Because the dose–response rela-
tionship found in women was not found in men, occurred at only the highest levels of lead, and
has no clear biologic explanation, further replication of this relationship is needed before it can be
considered believable. In conclusion, individuals with blood lead levels in the range of NHANES
II do not appear to have increased risk of cancer mortality. Key words: cancer, lead, mortality,
NHANES II, United States. Environ Health Perspect 110:325–329 (2002).[Online 28 February 
2002] http://ehpnet1.niehs.nih.gov/docs/2002/110p325-329jemal/abstract.html
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Articleswere provided on the public use ﬁle from the
National Center for Health Statistics), or into
two groups, divided at the sample-weighted
median. The log transformation was used to
adjust the lead levels for skewness. The 
following confounding covariates were used
as continuous or discrete variables at different
stages of analyses. Age at baseline, rounded to
the nearest year, was used as a continuous
variable. Smoking was categorized as never,
former, current < 1 pack, or current ≥ 1
pack. Poverty index was used as a continuous
variable determined by the Poverty Income
Ratio as defined by the U.S. Bureau of the
Census (Suitland, MD), a ratio of the total
income of the household to a multiple of the
total income necessary to maintain a family
with given characteristics on a nutritionally
adequate food plan (13). Alcohol consump-
tion was used as a continuous variable and
was obtained by summing the number of
times alcoholic beverages (beer, liquor, and
wine) were consumed per week. Region of
residence was recorded as Northeast,
Midwest, West, or South. Examination year
was categorized by year of the baseline survey
except for the last two examination years
(1979 and 1980), which were grouped into
one category because of the small number of
examinations in 1980. Examination year was
used as a stratifying variable because of
changing blood lead concentrations over the
baseline examination period (14).
We used Cox proportional hazard regres-
sion analysis (15) with baseline age at exami-
nation as the only covariate to obtain
age-adjusted relative hazards [henceforth
referred to as relative risks (RRs)] for all cancer
mortality by quartile of lead. Cox regression
was also used to estimate multivariate-adjusted
RRs for quartiles of lead, adjusting for con-
founding covariates (16) that included age at
examination, cigarette smoking, poverty
index, alcohol consumption, region of resi-
dence, year of examination, and sex. For site-
speciﬁc cancers, which were selected based on
suggested or suspected associations reported
previously (5,17), age-adjusted RRs and, for
some cancers (lung, esophagus, kidney, and
pancreas), age- and smoking-adjusted RRs
were obtained from Cox regression analyses
for blood lead levels above the (sex-com-
bined) median compared with below the
median. Lead was dichotomized above and
below the median instead of categorized into
quartiles because of small numbers of cases
for each site-speciﬁc cancer. 
Dose–response relationship of blood lead
and all cancer mortality was analyzed in two
ways: by testing for trend in the multivariate-
adjusted RRs across the quartiles of lead and
by modeling the log-transformed blood lead
as a continuous variable using a 5-knot cubic
regression spline (18) in the Cox regression
analysis. For tests of trend for the RRs over
the quartiles of blood lead, a linear term con-
sisting of the median values for each quartile
was placed in the Cox model instead of the
dummy variables for the quartiles. The test
for a dose–response relationship of lead using
the spline was based on a Wald test (19).
For all Cox regression analyses, we desig-
nated the survival times (calendar time) for
deceased individuals with all cancers or site-
specific cancers as the underlying causes of
death as event times, whereas the survival
times for persons who were deceased from
causes other than any form of cancer/site-
specific cancers or not known dead at the
end of the study period (31 December 1992)
were censored times. All analyses were done
for both sexes combined and for men and
women separately. 
NHANES II has a complex sample design
with multistage stratiﬁed cluster sampling and
sample weighting of study participants (20).
All analyses were performed using the soft-
ware package SUDAAN, Release 7.5 (21)
that takes into account the sample weights
and the complexity of the sample design in
the statistical modeling and inference (15).
All significance tests were two-sided using
0.05 as the level of statistical signiﬁcance.
Results
Table 1 presents selected characteristics at
baseline for NH2MS whites by quartile cate-
gory of blood lead measurement, showing
possible correlates of blood lead level. All esti-
mates in the table are weighted by the sample
weights. Note that the sample sizes are not
evenly distributed across the quartiles because
the quartile categories were determined by
the sample-weighted distribution of blood
lead level and not by the unweighted distrib-
ution. The sample included more women
(1,958) than men (1,770). For combined
sexes and for each sex separately, smoking
and alcohol consumption were higher with
increasing blood lead level, blood lead levels
were highest in the Northeast and lowest in
the South, and blood lead level decreased
over the course of the survey. Mean age
decreased in men but increased in women
with increasing blood lead level.
Table 2 presents age-adjusted only and
multivariate-adjusted RRs of mortality
from all cancer by quartile of lead, com-
pared with the risk in the ﬁrst quartile. The
multivariate-adjusted RRs were smaller than
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Table 1. Characteristics of the study cohort by sex and blood lead level.
Both sexes Males Females
Quartiles of blood lead Quartiles of blood lead Quartiles of blood lead
Characteristics 1 2 3 4 1 2 3 4 1 2 3 4
Sample size 745 902 1,028 1,053 144 342 523 761 601 560 505 292
Person-years 9,752 11,776 13,060 13,480 1,751 4,212 6,365 9,655 8,002 7,564 6,695 3,825
Median blood leada (µg/dL) 7.3 10.6 13.8 19.7 7.6 10.8 13.9 20.1 7.2 10.5 13.7 18.8
Age at baselinea,b (years) 48.3 49.3 49.9 49.6 50.8 48.9 48.9 48.6 47.8 49.2 50.9 52.3
Poverty index ratioa,b 2.6 2.9 3.1 2.9 2.7 3.1 3.2 2.9 2.6 2.7 3.0 2.9
Alcohol intakea,b (drinks/week) 1.2 2.2 2.7 4.4 1.8 2.9 3.4 5.2 1.0 1.8 2.0 2.5
Smoking at baselinea (%)
Never 55.8 44.5 31.7 23.0 37.3 29.6 23.1 16.9 59.9 52.9 40.7 39.3
Former 21.5 24.0 29.2 28.4 42.0 37.2 40.5 33.1 16.9 16.5 17.3 15.5
< 1 pack/day 16.5 23.9 24.4 27.3 7.9 21.8 19.3 26.1 18.4 25.1 29.8 30.6
≥ 1 pack/day 6.3 7.6 14.7 21.3 12.8 11.3 17.1 23.8 4.8 5.4 12.2 14.7
Regiona (%)
Northeast 16.0 24.1 25.9 29.2 15.2 20.4 25.9 30.0 16.1 26.2 26.8 27.9
Midwest 21.8 22.2 24.8 26.4 17.8 21.4 24.0 25.4 22.7 22.7 25.5 28.9
South 39.2 25.5 22.0 18.4 44.5 26.0 25.9 18.7 38.0 25.3 17.9 17.7
West 23.0 28.2 27.4 26.1 22.4 32.2 25.2 26.3 23.1 25.9 29.8 25.5
Year of baseline exama (%)
1976 13.9 19.8 22.3 36.4 12.2 14.8 18.8 33.4 14.3 22.6 25.9 44.7
1977 21.3 24.0 23.3 26.8 23.6 20.4 23.5 27.1 20.8 26.0 23.2 26.2
1978 19.1 27.7 32.5 24.2 12.3 28.9 30.1 24.7 20.6 27.0 35.1 22.8
1979–1980 45.7 28.5 21.9 12.6 51.9 35.9 27.7 14.9 44.3 24.3 15.8 6.4
aWeighted by sample weights from NHANES II. bMean value.their corresponding age-adjusted RRs.
Trends in the multivariate-adjusted RRs
were not statistically significant for both
sexes combined or for each sex separately.
Using Cox proportional hazard regression
analysis and a 5-knot cubic regression spline
to model the dose–response relationship
between log-transformed blood lead levels
and all cancer mortality, we found a non-
significant dose–response relationship
among both sexes combined (p = 0.17) and
among men only (p = 0.38). The spline
results for men are displayed graphically in
Figure 1. The conﬁdence intervals are wide,
and there appears to be no statistically signif-
icant dose relationship. In contrast, there
was a statistically significant dose–response
association between blood lead level and
cancer mortality among women (p = 0.001).
When the spline results are displayed graphi-
cally (Figure 2), there appears to be a thresh-
old effect of blood lead in women where the
risk becomes significantly elevated after the
93rd lead percentile, which corresponds to a
lead concentration of 24 µg/dL. This associ-
ation is not apparent in the quartile analysis
in Table 2 because the fourth quartile con-
tains too broad a range of lead levels.
However, if the fourth quartile is further
subdivided into four subquartiles (17,
18–19, 20–23, and ≥ 24 µg/dL), the multi-
variate-adjusted RRs for these subquartiles
are 0.72 (95% CI, 0.14–3.70) at the first
subquartile, 0.53 (95% CI, 0.15–1.88) at
the second subquartile, 1.44 (95% CI,
0.58–3.56) at the third subquartile, and 5.39
(95% CI, 2.19–13.24) at the fourth sub-
quartile when compared with the ﬁrst quar-
tile; the increase in risk begins at the third
subquartile, which is similar to the spline
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Table 2. Sample-weighted and age-adjusted RRs for all cancer mortality by quartiles of blood lead level. 
Sex/quartiles No. of Age-adjusted Multivariate-adjusted
(blood lead, µg/dL) deaths RRa 95% CI RR 95% CI ptrend
Both sexes
1 (≤ 9.8) 20 1.00 Referent 1.00 Referent 0.16
2 (9.9–12.9) 49 1.56 0.82–2.94 1.24 0.66–2.33
3 (13.0–16.9) 64 1.81 0.82–4.01 1.33 0.57–3.09
4 (≥ 17.0) 70 2.54 1.25–5.17 1.50 0.75–3.01
Males
1 (≤ 9.8) 4 1.00 Referent 1.00 Referent 0.57
2 (9.9–12.9) 24 2.19 0.69–6.95 2.00 0.63–6.33
3 (13.0–16.9) 42 3.01 0.91–9.91 2.61 0.77–8.83
4 (≥ 17.0) 47 2.99 0.92–9.69 2.02 0.63–6.46
Females
1 (≤ 9.8) 16 1.00 Referent 1.00 Referent 0.22
2 (9.9–12.9) 25 1.37 0.64–2.93 1.03 0.49–2.18
3 (13.0–16.9) 22 1.22 0.44–3.35 0.77 0.29–2.10
4 (≥ 17.0) 23 2.79 1.25–6.19 1.59 0.76–3.30
aRRs were not adjusted for confounding variables.
Figure 1. Relative risk of all cancer mortality for different blood lead levels
compared with referent blood lead level of 8 µg/dL (the 12.5th percentile)
among white men in the United States (NHANES II). The solid line shows the
ﬁtted 5-knot spline relationship; the dashed lines are the pointwise upper and
lower 95% conﬁdence limits. 
Figure 2. Relative risk of all cancer mortality for different blood lead levels
compared with referent blood lead level of 8 µg/dL (the 12.5th percentile)
among white women in the United States (NHANES II). The solid line shows
the ﬁtted 5-knot spline relationship; the dashed lines are the pointwise upper
and lower 95% conﬁdence limits.
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Blood lead level (µg/dL)analysis. It should be noted that in the third
and fourth subquartiles, there were only 7
and 10 cases, respectively, which indicates
the relatively small sample sizes that drive
these dose–response results. For the men
only, we also subdivided the fourth quartile
into four subquartiles (17–18, 19–20,
21–24, and ≥ 25 µg/dL) and estimated the
multivariate-adjusted RR for these subquar-
tiles as 1.42 (95% CI, 0.36–5.70 ) at the
ﬁrst subquartile, 2.15 (95 CI, 0.55–8.36) at
the second subquartile, 3.5 (95% CI,
1.02–11.05) at the third subquartile, and
1.13 (95% CI, 0.21–6.24) at the fourth sub-
quartile when compared with the ﬁrst quar-
tile. Although there is an increase in the
third subquartile, there is no discernible dose
response that agrees with the spline analysis. 
A test for the proportional hazard
assumption indicated that risks were con-
stant over the follow-up period among both
men and women combined (p = 0.25) and
among men (p = 0.54), but were marginally
significantly different (p = 0.04) among
women. However, further evaluation of the
relative risk for the ﬁrst-half and second-half
follow-up periods among women showed
virtually similar relative risks. Also, the possi-
bility of results being affected by individuals
with self-reported cancer or with unreported
or undiagnosed cancer at baseline was exam-
ined by excluding all participants with self-
reported cancer or by excluding all deaths
due to cancer within the ﬁrst year of follow-
up. The results were very similar to those
from the full cohort (data not shown). 
Table 3 presents the association of blood
lead level with selected site-specific cancer
mortality. None of the site-specific cancers
showed a statistically signiﬁcant excess risk.
Among the combined sexes and among men,
the risks increased for blood lead levels above
the median except for prostate cancer among
men and for brain cancer among both sexes
combined. Among women, there was no
clear pattern.
Discussion
In our analyses of the association of quartiles
of blood lead concentrations with all cancer
mortality in the white population of the
United States, we found that the risk of can-
cer mortality was not signiﬁcantly associated
with blood lead level among men and
women combined and among separate
analyses of men and women. A statistically
more powerful approach for determining a
dose–response relationship is to treat blood
lead as a continuous exposure using a 5-knot
cubic regression spline in the Cox regressions
(22). For both sexes combined and for men
only, the spline analysis found no signiﬁcant
dose–response relationship, agreeing with
the quartile analysis. However, for women
the spline analysis appears to show a thresh-
old effect at about the 94th percentile of
lead, corresponding to a blood concentration
of 24 µg/dL. There was no strong evidence
for an association of mortality from any of
the selected site-specific cancers with blood
lead level.
Whether lead causes cancer in humans is
not well established (1,5). The site-specific
cancers associated with lead exposure vary
among epidemiologic studies. Steenland and
Boffetta (5) did a meta-analysis of eight epi-
demiologic studies on cancer mortality or
incidence among workers with high occupa-
tional lead exposure. They reported an
increased risk for lung cancer (RR = 1.30;
95% CI, 1.15–1.46) and stomach cancer (RR
= 1.34; 95% CI, 1.14–1.57), but they found
little evidence of increased risk for kidney can-
cer (RR = 1.01; 95% CI, 0.72–1.42), brain
cancer (RR = 1.06; 95% CI, 0.81–1.40), and
all cancers combined (RR = 1.04; 95% CI,
1.00–1.09). Fu and Boffetta (17) performed
a similar meta-analysis of published data
using some of the studies common to the
preceding meta-analysis, and found signifi-
cant excess risk for all cancer, stomach can-
cer, lung cancer, and bladder cancer. Some
of our results were in agreement with the
summary results for all cancers by Fu and
Boffetta (17). However, it is noteworthy
that occupational lead exposure is much
higher than environmental exposure. For
example, the mean blood lead levels of the
occupational studies included in the above
meta-analyses ranged from 26 µg/dL to 80
µg/dL, compared with a weighted median
blood lead level of 13 µg/dL for our study
population.
We have no ready explanation why there
is an association of lead with mortality from
all cancers for women in the highest lead lev-
els but not for men, in view of the fact that
lead levels are higher among men than
among women across all age groups in the
United States (6). It has been suggested that
hereditary factors possibly related to lead
uptake and storage play a major role in deter-
mining the concentration of lead in blood,
especially in women (23). One may speculate
that there could also be a hereditary/genetic
factor that makes women more susceptible to
the role of lead in carcinogenesis. 
Blood lead levels have significantly
declined over time in the United States (24),
mainly due to removal of lead from gasoline
and soldered cans. Mean blood lead values in
the general population of the United States
decreased from 12.8 µg/dL in 1976–1980
(NHANES II) to 2.8 µg/dL in 1988–1991
(Phase 1 of NHANES III). However, blood
lead is still elevated among minority chil-
dren. In 1991–1994 (Phase 2 of NHANES
III), blood lead levels of ≥ 10 µg/dL
exceeded the maximum permissible concen-
tration established by the Centers for
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Table 3. Relative risks for selected site-speciﬁc malignant neoplasms among whites with blood lead mea-
surement at baseline, using the risk of cancer mortality in the lower 50th lead percentile as a reference.
Sex/anatomic site (ICD-9 code) Deaths RRa 95% CI p-Value
Both sexes combined
Esophagus (150) 7 3.7 0.2–89 0.39
Stomach (151) 5 2.4 0.3–19.1 0.40
Colon and rectum (153–154) 16 1.2  0.4–3.7 0.79
Pancreas (157) 12 3.6 0.6–19.8 0.14
Trachea, bronchus, and lung (162) 71 1.5 0.7–2.9 0.29
Breast (174)
Prostate (185)
Kidney (189) 7 1.1 0.2–5.1 0.91
Brain (191) 5 0.5 0.1–5.8 0.60
Men
Esophagus (150)b 5
Stomach (151) 4 3.1  0.3–37.4 0.37
Colon and rectum (153–154) 6 2.2 0.3–15.8 0.44
Pancreas (157) 6 3.5 0.4–32.5 0.26
Trachea, bronchus, and lung (162) 52 1.2 0.6–2.5 0.66
Prostate (185) 11 0.6 0.2–2.2 0.46
Kidney (189) 5 3.2 0.4–27.7 0.28
Brain (191) 1
Women
Esophagus (150) 2
Stomach (151) 1
Colon and rectum (153–154) 10 0.8  0.2–3.9 0.83
Pancreas (157) 6 3.8 0.3–40.1 0.27 
Trachea, bronchus, and lung (162) 19 2.5 0.7–8.4 0.14
Breast (174) 13 1.0 0.3–3.2 0.97
Kidney (189) 2
Brain (191) 4 0.7 0.1–6.8 0.73
aRelative risk from Cox proportional hazard regressions adjusted for age at examination for each site-specific cancer
site and for smoking for esophagus, pancreas, lung, and kidney cancers. bNo deaths in the lower 50th lead percentile to
estimate RR.Diseases Control (25) in 11.2% of non-
Hispanic black children ≤ 5 years of age
(26). Although the public health importance
of lead is declining in developed countries, it
is dramatically increasing in developing
countries (27–29). For example, over 90%
of mixed race children in inner-city Cape
Town, South Africa, have blood lead levels
≥ 10 µg/dL (30). In addition to lack of
awareness, policies, and regulations, reasons
for the rise of blood lead levels in developing
countries include increased exports of leaded
gasoline to these countries in search of new
markets as leaded gasoline is phased out in
developed countries (28,31). 
It is important to point out the limita-
tions in the database and analyses used for
our study. First, the NH2MS study is based
on a passive follow-up whereby persons not
found to be deceased were assumed alive.
Thus, there is a potential for misclassiﬁcation
of vital status. Comparison of the survival of
the NH2MS cohort to that of the U.S. pop-
ulation during the same time period to assess
how well mortality was ascertained in the
NH2MS study showed that cumulative sur-
vival probabilities for the NH2MS cohort
were generally higher than expected probabil-
ities calculated from the U.S. life table data
(10); however, the differences were very small
among whites. Second, lead level was based
on a one-time measurement that could have
random measurement error and could atten-
uate the estimated associations. In addition,
this measurement may not accurately reﬂect
cumulative exposure to lead but may only
provide an approximation to it. This is a par-
ticularly important point given the apparent
large decline in blood lead concentration in
the U.S. population over the course of the
survey because of increased use of unleaded
gasoline. Ideally, we would need repeated
measurements before and after baseline to
more accurately measure cumulative lead
exposure. Finally, the statistical power of this
study is limited by the relatively small cohort
size and follow-up time; as shown in Table 3,
the number of deaths for site-speciﬁc cancers
are too small to likely detect expected associa-
tion with blood lead. If the National Center
for Health Statistics performs future follow-
ups of this important cohort, the increase in
the number of cancer deaths will enlarge the
power of this cohort for detecting associa-
tions between blood lead and some of the
more common cancers. Also, because this is a
general population study, the blood lead lev-
els in this study are lower than would likely
be found among occupationally exposed
populations; this further reduces the statisti-
cal power. These limitations in the size and
exposure of this study sample may account
for some of the statistically insignificant
associations that were found. 
The apparent dose–response relationship
found only in women for the highest levels of
lead could be a chance finding or could be
due to residual or unmeasured confounding.
Because the dose–response relationship found
in women was not found in men, it occurred
at only the highest levels of lead, and has no
clear biologic explanation, further studies of
populations with sufficiently high levels of
lead exposure need to replicate our finding
among women before it is believable. In con-
clusion, individuals with blood lead levels in
the range of NHANES II do not appear to
have increased risk of cancer mortality. 
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